Biotech Values

[DewDiligence]

GKOS acquires AVDR for $26.68/sh in stock—a 56% premium based on today’s closing price of both stocks:

https://www.businesswire.com/news/home/20190807005773/en

Under the terms of the merger agreement, for each share of Avedro common stock they own, Avedro shareholders will receive an exchange ratio equivalent of 0.365 shares of Glaukos stock.

…Upon closing, Glaukos shareholders are expected to own approximately 85% of the combined company, with Avedro shareholders expected to own the remaining 15%.

The transaction is subject to customary closing conditions and regulatory approvals, including approval of the merger by stockholders of Avedro. Certain shareholders of Avedro, including OrbiMed, HealthQuest and LAV Agile, which collectively own approximately 41% of the outstanding shares of Avedro common stock, have entered into voting agreements to vote in favor of the transaction.

Based on the above, deal approval looks like a shoo-in unless some company steps up with a better offer.